SPN-812: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 222 ADHD patients ages 6-12 showed that once-daily 200, 300 and 400 mg oral SPN-812 each met the primary endpoint of reducing mean ADHD-RS-IV...